Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

84
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

9.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ECG-Synchronized Physiological Feedback During Obex Cavernoma Surgery: 2-D Operative Video.

World neurosurgery·2026
Same author

Chlorogenic acid attenuates skin senescence and UVR-induced photoaging via the modulation of mitochondrial function.

Journal of translational medicine·2026
Same author

Erratum to: Azvudine remodels the local immunosuppressive microenvironment and exhibits sustained anti-tumor effects in combination with anti-PD-1 therapies.

MedScience·2026
Same author

Microbial-Plant Synergy Underpins the Mitigation of Atrazine Phytotoxicity in Soybean by a Multifunctional Bacterial Seed Coating.

Journal of agricultural and food chemistry·2026
Same author

Distinct Oxidoreductases Orchestrate Indolethiophene Skeleton Formation and N-Hydroxylation-Mediated Bioactivation in Thienoxidolin Biosynthesis.

Angewandte Chemie (International ed. in English)·2026
Same author

Orbital hybridization-mediated nanozymes reverse cellular senescence for aged bone regeneration.

Biomaterials·2026
Same journal

Targeting SYK to alleviate MDSC-driven immunosuppression and augment anti-PD1 efficacy.

Science China. Life sciences·2026
Same journal

Microbial community structure and function and their linkages with methane production in sediments of thermokarst lakes on the Tibetan Plateau.

Science China. Life sciences·2026
Same journal

Roles of progestogens in influenza A virus-induced inflammatory responses.

Science China. Life sciences·2026
Same journal

RNA regulation in plants.

Science China. Life sciences·2026
Same journal

Translating genetic testing into fertility care.

Science China. Life sciences·2026
Same journal

A newly identified palmitoylation-related molecular signature acts as predictor and possible therapeutic target of atherosclerosis.

Science China. Life sciences·2026
See all related articles

Related Experiment Video

Updated: May 6, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.9K

Learning from berberine: Treating chronic diseases through multiple targets.

Jing Yao1, WeiJia Kong2, JianDong Jiang3

  • 1Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430023, China.

Science China. Life Sciences
|November 1, 2013
PubMed
Summary
This summary is machine-generated.

Berberine (BBR), a natural compound, shows promise for treating chronic diseases like diabetes and cancer. Its multiple-target effects offer a new strategy for complex conditions.

Keywords:
berberinechronic multifactorial diseasesdrug treatmentmultiple-target

Related Experiment Videos

Last Updated: May 6, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.9K

Area of Science:

  • Pharmacology
  • Natural Products
  • Chronic Disease Management

Background:

  • Current chemotherapy for multifactorial chronic diseases remains unsatisfactory.
  • Novel therapeutic agents with diverse mechanisms of action are needed.
  • Berberine (BBR), a botanical compound, has a history of medicinal use and emerging clinical evidence for chronic diseases.

Purpose of the Study:

  • To review the molecular mechanisms, clinical efficacy, and safety of berberine (BBR).
  • To explore BBR's therapeutic potential in type 2 diabetes, hyperlipidemia, heart diseases, cancers, and inflammation.
  • To highlight the multi-target strategy of BBR for treating complex chronic disorders.

Main Methods:

  • Literature review of existing clinical studies and molecular research on berberine.
  • Analysis of BBR's effects on various molecular targets relevant to chronic diseases.
  • Evaluation of safety and efficacy data from clinical trials.

Main Results:

  • Berberine (BBR) exhibits multiple-target effects, contributing to its efficacy across diverse chronic diseases.
  • Clinical studies suggest BBR is effective and safe for conditions including type 2 diabetes, hyperlipidemia, and certain cancers.
  • The synergistic action of BBR on multiple targets provides a comprehensive therapeutic approach.

Conclusions:

  • Berberine (BBR) represents a promising therapeutic agent for multifactorial chronic diseases.
  • A multi-target drug strategy, exemplified by BBR, may be crucial for successful treatment of complex conditions.
  • Further research into BBR's mechanisms and applications is warranted.